D-Xylose (Wood Sugar): A Comprehensive Encyclopedic Reference
1. Identity, Chemical Characterization, and Forms
Nomenclature and Chemical Identity
Xylose (from the Ancient Greek ξύλον, xylon, meaning "wood") is a common monosaccharide — that is, a simple sugar — classified as an aldopentose, meaning that it contains five carbon atoms and includes an aldehyde functional group, at least in its open-chain form. It is a monosaccharide of the aldopentose type consisting of five carbon atoms and an aldehyde functional group. Its IUPAC name is (2R,3S,4R)-2,3,4,5-tetrahydroxypentanal in open-chain form. Its PubChem CID is 135191, with molecular formula C₅H₁₀O₅ and synonyms including D-xylopyranose, xylopyranose, and xylopyranoside. Its molecular weight is 150.13 g/mol. The biologically predominant natural enantiomer is D-xylose; its mirror image, L-xylose, occurs at negligible levels in nature and has no known nutritional role.
The acyclic form of xylose has the chemical formula HOCH₂(CH(OH))₃CHO. Cyclic hemiacetal isomers are more prevalent in solution. These cyclic isomers include the pyranoses, which feature six-membered C₅O rings, and the furanoses, which feature five-membered C₄O rings (with a pendant CH₂OH group). In aqueous solution the pyranose form (D-xylopyranose) predominates. Due to its free aldehyde group, xylose qualifies as a reducing sugar. D-xylose has a melting point of 144–145 °C. It is a white, water-soluble solid.
Natural Sources and Distribution
Xylose is abundant in biomass and is one of the most abundant sugars in nature. In the form of xylan polymers, the pentose sugar D-xylose is a structural component of plant cell walls. Xylose is the main building block for the hemicellulose xylan, which comprises about 30% of some plants (birch, for example) — far less in others (spruce and pine have about 9% xylan). It occurs naturally in various plant materials, particularly in wood and straw.
The top food sources high in D-xylose include corn cobs, birchwood, and certain fruits such as strawberries and raspberries. In hardwood species, 75–95% of the hemicellulose is of the glucuronoxylan type; in its native state, hardwood hemicellulose has an average degree of polymerization of approximately 200, and 80–90% of the principal monomer components are anhydrous D-xylose units. Xylose is otherwise pervasive, being found in the embryos of most edible plants.
Xylose is also the first saccharide added to serine or threonine in the proteoglycan type O-glycosylation, and so it is the first saccharide in biosynthetic pathways of most anionic polysaccharides such as heparan sulfate and chondroitin sulfate. This role in proteoglycan synthesis is distinct from its dietary or fermentable roles and underscores its relevance in mammalian cell biology.
Commercial Forms and Preparations
Xylose is a sugar isolated from wood and is widely used as a diabetic sweetener in food and beverage. D-xylose, also known as wood sugar, has the chemical formula C₅H₁₀O₅, with a molecular appearance of white crystalline powder or colorless needles, and serves as a crucial monosaccharide in various biochemical processes, used in food as a sweetener and preservative. Commercially, D-xylose is produced chiefly by acid hydrolysis of xylan-rich plant biomass such as corncobs and hardwood chips, followed by purification. D-xylose powder finds applications in pharmaceuticals as an excipient and in the production of biofuels, contributing to renewable energy efforts.
- Pure crystalline powder: The most common supplement and food-grade form.
- Solution (aqueous): Used clinically in the D-xylose absorption test and in research.
- As a precursor: D-xylose serves as a starting material for xylitol production, a popular sugar substitute.
- Xylooligosaccharides (XOS): XOS are sugar oligomers made up of 2–6 xylose units linked through β-(1→4)-linkages. These represent a distinct, though closely related, category of prebiotic preparations derived from xylan hydrolysis.
2. Historical and Traditional Use
Scientific Discovery and Early Characterization
Xylose was first isolated from wood by Finnish scientist Koch in 1881, but it first became commercially viable, with a price close to sucrose, in 1930. The name xylose (Greek xylon, meaning wood) originates from the isolation of the sugar from wood by Koch, and xylose is also known as wood sugar. The chemical reduction of D-xylose yielding xylitol was performed in 1891 by Emil Fischer, marking early carbohydrate-chemistry work that established the stereochemical relationships among pentose sugars.
Traditional and Pre-modern Uses
Unlike many herbal or botanical supplements, D-xylose was not used as an isolated compound in traditional medicine prior to the 20th century. Its precursor polymers — xylans and hemicellulosic plant materials — are inherently present in traditional diets wherever whole plant foods, woody vegetables, cereal straws, and plant-fiber-rich preparations were consumed. No documented indigenous tradition employed purified xylose as a therapeutic agent; its isolation was a product of 19th-century analytical chemistry. The monosaccharide existed in consumed plant foods as a bound polymer and was incidentally ingested. Its identification as a discrete entity, and subsequent study of its physiological effects, are products of modern biochemistry and food science.
The predominant everyday nutritional usage of xylose is as a parent sugar alcohol from which another sugar alcohol — xylitol — can be derived and used as an extremely common food additive or sweetener to be used in place of regular sugars. As early as the 1930s, after xylose became commercially available, interest grew in its potential as a low-calorie sweetener suitable for people with diabetes. The D-xylose absorption test, which began appearing in the clinical literature in the 1950s (first described in the New England Journal of Medicine by Benson et al. in 1957), formalized the medical use of the sugar as a diagnostic probe.
3. Key Constituents, Active Compounds, and Mechanisms of Action
Chemical Identity as an Active Compound
D-xylose is itself the biologically active molecule of interest; it does not contain "secondary metabolites" in the sense of herbal preparations. Its physiological effects derive directly from its monosaccharide structure, metabolic fate, and enzymatic interactions. The following mechanisms are established or hypothesized:
Sucrase Inhibition
L-arabinose and D-xylose share a common functionality — the inhibition of sucrose hydrolysis in the brush border of the small intestine by uncompetitive inhibition of the enzyme sucrase. D-xylose was as potent as L-arabinose in inhibiting sucrase activity, and both showed no inhibitory effect on the activities of intestinal maltase, isomaltase, trehalase, lactase, and glucoamylase, or pancreatic amylase. This specificity distinguishes D-xylose from classical alpha-glucosidase inhibitors such as acarbose, which competitively inhibited sucrase activity and also inhibited intestinal maltase, glucoamylase, and pancreatic amylase.
Metabolic alterations including postprandial hyperglycemia have been implicated in the development of obesity-related diseases; xylose is a sucrase inhibitor suggested to suppress the postprandial glucose surge. Importantly, the suppressive effect of D-xylose on the increase of blood glucose after sucrose loading was 2.4 times less than that of L-arabinose, probably due to intestinal absorption of the former. In other words, because D-xylose is partially absorbed across the intestinal wall, some of the compound is removed from the gut lumen before it can fully exert its sucrase-inhibiting effect.
Human Metabolism and Fate
The human body absorbs D-xylose through the small intestine via passive diffusion and active transport mechanisms, and once absorbed, D-xylose enters the bloodstream. Unlike glucose, humans cannot fully metabolize D-xylose for energy. A significant fraction passes unmodified through renal filtration and is excreted in urine — a property that underpins the D-xylose absorption diagnostic test.
For the portion that is metabolized, the following pathway applies: xylose reductase (XR) and xylitol dehydrogenase (XDH) are the first two enzymes in the oxidoreductase pathway. XR reduces D-xylose to xylitol using NADH or NADPH; xylitol is then oxidized to D-xylulose by XDH using the cofactor NAD; and in the last step, D-xylulose is phosphorylated by an ATP-utilizing kinase to result in D-xylulose-5-phosphate, which is an intermediate of the pentose phosphate pathway.
D-xylulokinase (XK; EC 2.7.1.17) catalyzes the ATP-dependent phosphorylation of D-xylulose to produce xylulose 5-phosphate. In mammals, XK is the last enzyme in the glucuronate-xylulose pathway, active in the liver and kidneys, and is linked through its product Xu5P to the pentose phosphate pathway. XK may play an important role in metabolic disease, given that Xu5P is a key regulator of glucose metabolism and lipogenesis.
Proteoglycan Synthesis
Xylose is the first saccharide added to serine or threonine in the proteoglycan type O-glycosylation, and so it is the first saccharide in biosynthetic pathways of most anionic polysaccharides such as heparan sulfate and chondroitin sulfate. This endogenous biochemical role in connective tissue biology is a property of the sugar itself within mammalian cells and is distinct from dietary intake effects.
Prebiotic Fermentation (via XOS)
XOS are mixtures of oligosaccharides containing β-1,4-linked xylose residues which naturally occur in bamboo shoots, fruits, vegetables, milk, and honey. For prebiotics, glucans and fructans are well proven, and evidence is building on the prebiotic effects of other substances, including oligomers of mannose, glucose, xylose, pectin, starches, human milk, and polyphenols. Both free D-xylose (which largely escapes upper GI absorption) and XOS can reach the colon, where colonic bacteria ferment them. This review article delineates various types of prebiotics, including xylooligosaccharides, and elucidates their impact on the gut microbiota composition, particularly focusing on producing short-chain fatty acids and modulating the gut microbiota towards a health-promoting composition.
4. Scientific Evidence by Area of Use
4.1 Diagnostic Medicine: The D-Xylose Absorption Test
Overview: The D-xylose absorption test is a medical test performed to diagnose conditions that present with malabsorption of the proximal small intestine due to defects in the integrity of the gastrointestinal mucosa. D-xylose is a monosaccharide, or simple sugar, that does not require enzymes for digestion. Because it is absorbed through the intact mucosa but not significantly metabolized by a healthy intestine, the amount appearing in blood and urine after oral administration reflects mucosal integrity.
D-xylose absorption testing is a simple, low-cost method of screening for small intestinal malabsorption. In general, D-xylose excretion is associated with disturbance of the intestinal wall of the upper jejunum. Low readings are found with adult coeliac disease but rarely with regional enteritis.
Clinical study details: One hundred ninety-seven 1-hour blood xylose absorption tests with 5 g of D-xylose were performed on 171 infants and children for the evaluation of malabsorption. The mean ± 1 SD blood xylose level in 78 controls was 37.0 ± 7.7 mg/dl, and in 71 patients with post-infectious diarrhea was 28.4 ± 11.0 mg/dl. These results confirm that the 1-hour blood xylose absorption test is a sensitive indicator of severe intestinal damage, and intestinal biopsy should be considered in all patients with a 1-hour blood xylose level less than 20 mg/dl.
Optimal discrimination between normal and impaired xylose absorption is achieved by measuring blood xylose levels 1 hour after oral administration and then correcting the results to a constant body surface area. The test is of particular value in the elderly because surface-area-corrected 1-hour blood xylose levels are independent of age, eliminating the expected and observed declines in renal function and urinary xylose excretion in that age group. A study of 51 consecutive patients investigating the accuracy of the serum test found that the addition of a 3-hour D-xylose serum level of less than 22.5 mg/dL to conventional 1-hour D-xylose determination greatly improves the D-xylose test for malabsorption screening.
In cases of bacterial overgrowth, the values of D-xylose absorption return to normal after treatment with antibiotics. In contrast, if the D-xylose urinary excretion is not normal after a course of antibiotics, then the problem must be due to a non-infectious cause of malabsorption such as celiac disease.
Xylose testing is no longer routinely ordered to check for malabsorption, and it may not be available everywhere. It has been largely supplanted by serological tests, intestinal biopsy, and breath tests in many centers, though it retains utility in certain populations and settings.
Evidence strength: Well-established clinical application with decades of validation in human studies. However, it is a diagnostic procedure, not a nutritional supplement application.
4.2 Postprandial Glycemic Control and Sucrase Inhibition
Overview: L-arabinose and D-xylose have been hypothesized to inhibit intestinal sucrase activity, delay sucrose digestion, and reduce glycaemic and insulinaemic responses. However, few human studies have assessed this using realistic foods.
Human study 1 (Bae et al., 2011 — PMC): Randomized double-blind cross-over studies were conducted to examine the effect of D-xylose on postprandial glucose and insulin response following the oral glucose tolerance test. In study 1, the overnight-fasted study subjects (n = 49) consumed a test sucrose solution (50 g sucrose in 130 ml water) containing 0, 5, or 7.5 g D-xylose powder. 5 g or 7.5 g xylose supplementation during a 50 g oral sucrose challenge effectively reduced serum glucose and insulin increases, and glucose absorption was delayed. The 5 g xylose-containing solutions exhibited significantly lower area under the glucose curve (AUCg) and area under the insulin curve (AUCi) values from 0–15 min, 0–30 min, 0–45 min, 0–60 min, 0–90 min, and 0–120 min. In conclusion, xylose showed an acute suppressive effect on the postprandial glucose and insulin surges.
Human study 2 (Moon et al. / Trials journal, 2016 — PMC): This study assessed the acute effect of xylose on postprandial glycemia in subjects with normal glucose levels or prediabetics who consumed sucrose drinks that contained 5 g (Test 1; sucrose:xylose = 10:1), 3.33 g (Test 2; sucrose:xylose = 15:1), or 2.5 g (Test 3; sucrose:xylose = 20:1) of D-xylose, with a one-week separation interval. Normal subjects in all test groups exhibited a significant decrease in serum glucose levels at 15 min and 30 min after consuming the xylose-containing drinks compared to the control group. The test 1 group also exhibited a significantly lower insulin area under the curve than the control group; hyperglycemic subjects (n = 50) in all test groups exhibited a significant decrease in serum glucose levels at 30 min compared to the control group. However, the test 1 group exhibited a significant increase in serum glucose levels at 120 min compared to the control group, and glucose-related markers did not significantly differ in each group.
A sucrose drink containing 10% (w/w) D-xylose reduced the glycemic index (GI) by 21.4% and insulin secretion by 21.3% in healthy individuals.
Human study 3 (Halschou-Jensen et al., Food & Nutrition Research, 2021 — PMC): The effects of adding L-arabinose and D-xylose on glucose homeostasis were investigated using a fruit-based drink. Fifteen males participated in two double-blind, randomized cross-over experiments; in experiment A, three drinks were tested: (1) L-arabinose, (2) D-xylose, and (3) control drink. Results showed that D-xylose showed similar effects on glycaemic responses to L-arabinose, consistent with other studies in which D-xylose was added to sucrose in water. Bae et al. tested 5 and 7.5 g D-xylose plus 50 g sucrose in 130 mL water and found lower glucose and insulin concentrations at 15, 30, and 45 min, as well as an approximately 20% lower AUC of glucose and insulin.
Evidence strength: Moderate. Multiple small-to-medium randomized, double-blind, crossover human trials demonstrate acute reductions in postprandial glucose and insulin when D-xylose is co-consumed with sucrose. The effect is mechanistically coherent (sucrase inhibition). Limitations include: most studies test acute single-dose effects rather than long-term metabolic outcomes; sample sizes are modest (n = 15–75); findings are largely from Korean research groups; and the real-food matrix effects appear to attenuate the response compared to sugar-water solutions. No large-scale or multi-center RCTs examining long-term glycemic outcomes in diabetes patients have been published.
4.3 Prebiotic Effects and Gut Microbiota Modulation (XOS)
Overview: Xylose-based oligosaccharides (XOS) have been studied as prebiotics in human trials. Although XOS are not identical to monomeric D-xylose, they are direct hydrolytic products of xylan, and their prebiotic action involves fermentation of xylose residues by colonic bacteria. Evidence from free xylose specifically as a prebiotic in humans is limited; most microbiota research uses XOS.
Human RCT (Childs et al., 2016 — PMC): This study evaluated the effect of the prebiotic xylooligosaccharide (XOS) on the gut microbiota in both healthy and prediabetic subjects. Pre-DM (n = 13) or healthy (n = 16) subjects were randomized to receive 2 g/day XOS or placebo for 8 weeks. XOS significantly decreased or reversed the increase in abundance of Howardella, Enterorhabdus, and Slackia observed in healthy or Pre-DM subjects, and the abundance of the species Blautia hydrogenotrophica was lower in pre-DM subjects while XOS increased its abundance. In Pre-DM, XOS showed a tendency to reduce OGTT 2-hour insulin levels (P = 0.13), but had no effect on body composition, HOMA-IR, serum glucose, triglyceride, satiety hormones, and TNFα.
Human RCT (Sheu et al., 2016 — PMC): A randomized, controlled study evaluated the prebiotic effects of XOS on fecal microbiota in healthy human volunteers after a period of 6 weeks of daily consumption, since the prebiotic evidence derived from human trials is still insufficient.
Evidence strength: Preliminary. Evidence from human trials with XOS (2 g/day for 8 weeks; 6 weeks) shows significant gut microbiota modulation, including increased abundance of beneficial taxa. However, the number of human trials is small, sample sizes are limited, the prebiotic classification of free monomeric xylose (as opposed to XOS) in humans has not been formally established, and long-term clinical endpoints (e.g., disease outcomes) have not been evaluated. A 2019 review in Nature Reviews Gastroenterology & Hepatology noted that evidence is building on the prebiotic effects of oligomers of xylose but placed these behind the more established glucan- and fructan-based prebiotics.
4.4 Role in Connective Tissue and Proteoglycan Biology
Xylose is the first saccharide added to serine or threonine in the proteoglycan type O-glycosylation, making it the first saccharide in the biosynthetic pathways of most anionic polysaccharides such as heparan sulfate and chondroitin sulfate. This is an endogenous biochemical function; in vivo, xylose is synthesized by the body from UDP-xylose. Whether exogenous oral xylose supplementation meaningfully influences proteoglycan biosynthesis in humans has not been demonstrated in published clinical trials. Claims that oral xylose "supports cartilage" via this mechanism remain speculative in the absence of controlled human data.
4.5 Low-Calorie Sweetener / Diabetic Nutrition
D-xylose is widely used as a diabetic sweetener in food and beverage. As a natural low-calorie sweetener, D-xylose has a sweetness intensity that is a fraction of sucrose, making it useful for sugar reduction strategies in food and beverage formulations. Unlike other sugar alcohols, D-xylose has a lower sweetness capacity and tends to turn brown when heated — a Maillard reaction property used in food manufacturing for flavor and color development. Because a significant proportion of ingested D-xylose is excreted in urine rather than metabolized for energy, its effective caloric contribution is lower than sucrose. However, precise caloric values vary and the extent of urinary excretion depends on intestinal integrity and dose.
Evidence strength: The use of D-xylose as a lower-glycemic-impact sugar substituting for sucrose is well-supported by the mechanism of sucrase inhibition and human clinical crossover trials described in Section 4.2. Its formal regulatory status as a diabetic food ingredient varies by country.
5. Body Systems and Health Areas Associated with D-Xylose
- Gastrointestinal / Diagnostic: Used in the D-xylose absorption test to assess small intestinal mucosal integrity and diagnose malabsorption syndromes including celiac disease and bacterial overgrowth.
- Metabolic / Endocrine: Acute sucrase inhibition reduces postprandial glucose and insulin responses when co-administered with sucrose.
- Gut Microbiota: As a xylose polymer (XOS), it functions as a prebiotic substrate for colonic Bifidobacterium and Lactobacillus species, producing short-chain fatty acids.
- Connective Tissue (biochemical): Endogenously incorporated as the initiating sugar in O-glycosylation pathways forming chondroitin sulfate and heparan sulfate.
- Hepatic Metabolism: Partially metabolized in liver and kidneys via the glucuronate-xylulose pathway feeding into the pentose phosphate pathway.
6. Dosage Forms and Dosages Reported in Studies
Dosages below are reported only as stated in primary sources. No therapeutic dosage recommendation is implied.
- D-xylose absorption test (diagnostic):
All patients received D-xylose, 10 g intravenously and 25 g orally, on two separate occasions in one study design. In pediatric studies, blood xylose level 60 min after an oral dose of 10 g/m² xylose was compared with jejunal mucosal histology in 56 children. In another study, 197 one-hour blood xylose absorption tests with 5 g of D-xylose were performed on 171 infants and children.
- Glycemic response suppression (clinical trials):
Study subjects (n = 49) consumed a test sucrose solution (50 g sucrose in 130 ml water) containing 0, 5, or 7.5 g D-xylose powder. In the crossover study by Moon et al., sucrose drinks contained 5 g (sucrose:xylose = 10:1), 3.33 g (sucrose:xylose = 15:1), or 2.5 g (sucrose:xylose = 20:1) of D-xylose.
- XOS prebiotic intervention:
Pre-DM (n = 13) or healthy (n = 16) subjects were randomized to receive 2 g/day XOS or placebo for 8 weeks.
7. Safety Considerations and Interactions
General Tolerability
At doses used in clinical glycemic studies (2.5–7.5 g per serving co-administered with sucrose), D-xylose appears well tolerated in published trials, with no serious adverse events reported. Because a proportion is excreted in urine, it contributes fewer metabolizable calories than an equivalent mass of sucrose.
Gastrointestinal Effects
As with other poorly-absorbed carbohydrates, higher doses of xylose and its oligomers may cause gastrointestinal symptoms. In animal toxicology studies with XOS, in mid-dose groups, transitional diarrhea was observed in the initial 1–2 weeks; in high-dose groups, diarrhea and/or vomiting were observed episodically over the duration of treatment, but these disappeared after XOS was withdrawn in the recovery period. The NOAEL in the XOS chronic dog study was 2500 mg/kg body weight per day.
Renal Considerations
Because D-xylose is substantially excreted by the kidney, its use as a diagnostic agent requires caution in patients with renal impairment, in whom reduced urinary excretion produces false-positive results (suggesting malabsorption). D-xylose absorption testing is a simple, low-cost method of screening for small intestinal malabsorption, but the optimum method to measure D-xylose absorption — serum vs. urine testing — is uncertain, and renal function directly affects test interpretation.
Distinction from Xylitol Toxicity
D-xylose should not be confused with xylitol, its reduced sugar-alcohol derivative. While xylitol has well-documented gastrointestinal side effects at higher oral doses and is acutely toxic to dogs, D-xylose has a distinct metabolic profile. In humans, xylitol is endogenously produced through the pentose phosphate pathway; the PPP is up-regulated during the reperfusion phase of ischaemic-reperfusion injury, such as occurs in cardiovascular disease or shock, thereby increasing metabolites produced in the PPP including xylitol. This endogenous interconversion means that plasma xylitol levels may be markers of PPP activity, not necessarily reflecting dietary xylose intake.
Interactions
No pharmacokinetic drug interactions with D-xylose as a dietary supplement have been established in published human clinical data. In the diagnostic test context, several factors are documented to reduce test accuracy: the test is occasionally misleading, giving both false positive and false negative results; problems with the test include the fact that the Roe and Rice method of D-xylose analysis is non-specific and cross-reacts partially with glucose. Aspirin (acetylsalicylic acid) has been noted in older literature to impair xylose absorption and may affect test results. Patients with ascites may have altered xylose distribution volumes. Antibiotic treatment can normalize an abnormal test result in cases where bacterial overgrowth is the cause of apparent malabsorption.
Regulatory Status
D-xylose is generally recognized as safe (GRAS) in the United States for use as a food ingredient and flavoring. It finds application in processing industries as a sugar substitute, preservative, pet food, candies, beverages, food and animal feed, and as a reagent in cosmetics and technical applications. It is used as a pharmaceutical excipient in some countries. No formal upper tolerable intake level has been established by the NIH Office of Dietary Supplements or EFSA specifically for D-xylose as a dietary supplement in healthy adults.
References
Volver